| |
The 2011 Frost & Sullivan Europe Competitive Strategy Leadership Award in Bio Pharmaceutical Contract Manufacturing is presented to Boehringer-Ingelheim. The company is recognised for having steadily established itself as one of the largest and most successful bio pharmaceutical contract manufacturing organistions (CMOs), both globally and in Europe.
"Boehringer-Ingelheim's extensive know-how and services, combined with its technological excellence and strong product pipeline, have underlined its competitive excellence," notes Frost & Sullivan Research Analyst Aiswariya Chidambaram. "Strategic alliances and support services for start-ups have further reinforced its strategic superiority in the bio pharmaceutical contract manufacturing market."
Boehringer-Ingelheim has a strong presence of more than 3 decades in the global bio pharmaceutical industry. "Backed by more than 15 years experience in the contract manufacturing business, it currently accounts for 23 per cent of sales revenues and 23 per cent of manufacturing capacity in the global bio pharmaceutical contract manufacturing market," states Chidambaram.
"The company is positioned as a 'one-stop-shop' service supplier of bio pharmaceutical products and services, ranging from high expression systems to fill and finish services," remarks Chidambaram.
To date, Boehringer-Ingelheim has successfully introduced 19 DNA derived bio pharmaceutical products - significantly higher than any other company in the bio pharmaceutical contract manufacturing market. In addition to its strong in-house technology, strategic alliances, such as those with Pfenex Inc, Fresenius Kabi, Probiogen AG, and VTU Technology, have enabled the company to offer cutting-edge solutions.
Four of the bio pharmaceuticals produced by Boehringer-Ingelheim for its customers rank among the global top twenty bio pharmaceutical products. These include Enbrel produced for Amgen Inc and Pfizer/Wyeth Pharmaceuticals, Synagis for MedImmune Inc, Betaferon for Bayer Health Care and Erbitux for Merck Serono.
Boehringer-Ingelheim counts among its customers, many of the world's leading research-oriented bio pharmaceutical companies and pharmaceutical organisations such as Genentech Inc., Genzyme Corp, GlaxoSmithKline, InterMune Inc., Bayer Health Care, Pfizer Inc. and Amgen Inc.
The availability of world-class expertise, coupled with strategies and processes designed to suit individual customer needs, makes Boehringer-Ingelheim the ideal choice for most bio pharmaceutical companies. Strict adherence to timelines and a time-to-market approach, along with the involvement of clients at all stages of development, underpins high levels of customer satisfaction.
"While the company's 'time-to-market' approach facilitates fast-track process development to commercial scale and early market supply, the 'step-by-step' approach is practiced for highly innovative projects, associated with a certain degree of risk, based on the requirements of the customers," concludes Aiswariya Chidambaram. "The integrated team approach at Boehringer-Ingelheim, wherein experts from different teams work in unison, ensures that customers are guaranteed services with maximum efficiency, safety and cost-effectiveness."
The Competitive Strategy Leadership Award is presented to the company that has excelled in the following criteria: leverage of competitive intelligence, execution of competitive strategy, impact on market share, competitive brand positioning (brand strength and unique market position) and impact on customer satisfaction/value.
Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
About Boehringer-Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since its foundation in 1885, the family-owned company has been committed for more than 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
Today, Boehringer Ingelheim is one of the world's leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its global manufacturing facilities for mammalian cell culture and microbial fermentation. Boehringer Ingelheim has brought 19 molecules to market and has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products.
About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.
|
emily.bailey[.]frost.com 
